Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2006 Jul;98(7):1126–1135.

Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease.

Jerry Johnson 1, Joan Weinryb 1
PMCID: PMC2569481  PMID: 16895283

Abstract

Arthritis is the leading cause of disability in the United States. Osteoarthritis, the most common form of arthritis, is a degenerative joint disease affecting both whites and African Americans similarly. African Americans have a high incidence rate of comorbidities, including hypertension, cardiovascular disease (CVD) risk factors and diabetes. Treatment of osteoarthritic pain in patients with comorbidities is often complicated by potential safety concerns. Traditional nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase 2 (COX-2) specific NSAIDs have been shown to increase blood pressure in hypertensive patients taking antihypertensive medications. Patients with CVD risk factors taking low-dose aspirin for secondary prevention may be at increased risk for gastrointestinal bleeding with NSAIDs. Diabetics face an increased risk of renal complications. Because NSAIDs are associated with adverse renal effects, they should be used cautiously in patients with advanced renal disease. Acetaminophen is the most appropriate initial analgesic for African Americans with chronic osteoarthritic pain and concurrent hypertension, CVD risk factors or diabetes, and is recommended by the American College of Rheumatology as first-line treatment. Many of the adverse effects commonly associated with NSAIDs are not associated with acetaminophen. Safety concerns surrounding pharmacologic treatment of osteoarthritis in African Americans are reviewed.

Full text

PDF
1126

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad Syed R., Kortepeter Cindy, Brinker Allen, Chen Min, Beitz Julie. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537–544. doi: 10.2165/00002018-200225070-00007. [DOI] [PubMed] [Google Scholar]
  2. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71–86. doi: 10.1136/bmj.324.7329.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blot W. J., McLaughlin J. K. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137–142. [PubMed] [Google Scholar]
  4. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M. B., Hawkey C. J., Hochberg M. C. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
  5. Bonkovsky H. L., Kane R. E., Jones D. P., Galinsky R. E., Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology. 1994 May;19(5):1141–1148. [PubMed] [Google Scholar]
  6. Bonkowsky H. L., Mudge G. H., McMurtry R. J. Chronic hepatic inflammation and fibrosis due to low doses of paracetamol. Lancet. 1978 May 13;1(8072):1016–1018. doi: 10.1016/s0140-6736(78)90740-7. [DOI] [PubMed] [Google Scholar]
  7. Brook Robert D., Kramer Michael B., Blaxall Burns C., Bisognano John D. Nonsteroidal Anti-Inflammatory Drugs and Hypertension. J Clin Hypertens (Greenwich) 2000 Oct;2(5):319–323. [PubMed] [Google Scholar]
  8. Bruyere Olivier, Pavelka Karel, Rovati Lucio C., Deroisy Rita, Olejarova Marta, Gatterova Jindriska, Giacovelli Giampaolo, Reginster Jean-Yves. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause. 2004 Mar-Apr;11(2):138–143. doi: 10.1097/01.gme.0000087983.28957.5d. [DOI] [PubMed] [Google Scholar]
  9. Catella-Lawson F., Reilly M. P., Kapoor S. C., Cucchiara A. J., DeMarco S., Tournier B., Vyas S. N., FitzGerald G. A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809–1817. doi: 10.1056/NEJMoa003199. [DOI] [PubMed] [Google Scholar]
  10. Centers for Disease Control and Prevention (CDC) Prevalence and impact of arthritis by race and ethnicity--United States, 1989-1991. MMWR Morb Mortal Wkly Rep. 1996 May 10;45(18):373–378. [PubMed] [Google Scholar]
  11. Centers for Disease Control and Prevention (CDC) Prevalence of arthritis--United States, 1997. MMWR Morb Mortal Wkly Rep. 2001 May 4;50(17):334–336. [PubMed] [Google Scholar]
  12. Chalmers J. P., West M. J., Wing L. M., Bune A. J., Graham J. R. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A. 1984;6(6):1077–1093. doi: 10.3109/10641968409039582. [DOI] [PubMed] [Google Scholar]
  13. Coggon D., Langman M. J., Spiegelhalter D. Aspirin, paracetamol, and haematemesis and melaena. Gut. 1982 Apr;23(4):340–344. doi: 10.1136/gut.23.4.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dart R. C., Kuffner E. K., Rumack B. H. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther. 2000 Mar;7(2):123–134. doi: 10.1097/00045391-200007020-00009. [DOI] [PubMed] [Google Scholar]
  15. Dart R. C., Kuffner E. K. Use of acetaminophen in alcoholic patients: comment on the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis. Arthritis Rheum. 2001 Oct;44(10):2449–2456. doi: 10.1002/1529-0131(200110)44:10<2449::aid-art413>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  16. Dart R. C. The use and effect of analgesics in patients who regularly drink alcohol. Am J Manag Care. 2001 Dec;7(19 Suppl):S597–S601. [PubMed] [Google Scholar]
  17. Dart Richard C., Kuffner Edwin. Alcohol and acetaminophen hepatotoxicity. Arch Intern Med. 2003 Jan 27;163(2):244–245. doi: 10.1001/archinte.163.2.244-c. [DOI] [PubMed] [Google Scholar]
  18. Deeks Jonathan J., Smith Lesley A., Bradley Matthew D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002 Sep 21;325(7365):619–619. doi: 10.1136/bmj.325.7365.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Faich G. Kidney failure and analgesic drugs. N Engl J Med. 1995 Jun 1;332(22):1514–1516. [PubMed] [Google Scholar]
  20. Feenstra Johan, Heerdink Eibert R., Grobbee Diederick E., Stricker Bruno H. Ch. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002 Feb 11;162(3):265–270. doi: 10.1001/archinte.162.3.265. [DOI] [PubMed] [Google Scholar]
  21. García Rodríguez Luis Alberto, Hernández-Díaz Sonia. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003 Mar;14(2):240–246. doi: 10.1097/01.EDE.0000034633.74133.C3. [DOI] [PubMed] [Google Scholar]
  22. Gurwitz J. H., Avorn J., Bohn R. L., Glynn R. J., Monane M., Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994 Sep 14;272(10):781–786. [PubMed] [Google Scholar]
  23. Hansson L., Zanchetti A., Carruthers S. G., Dahlöf B., Elmfeldt D., Julius S., Ménard J., Rahn K. H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–1762. doi: 10.1016/s0140-6736(98)04311-6. [DOI] [PubMed] [Google Scholar]
  24. Henrich W. L., Agodoa L. E., Barrett B., Bennett W. M., Blantz R. C., Buckalew V. M., Jr, D'Agati V. D., DeBroe M. E., Duggin G. G., Eknoyan G. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996 Jan;27(1):162–165. doi: 10.1016/s0272-6386(96)90046-3. [DOI] [PubMed] [Google Scholar]
  25. Horowitz R. S., Wilson V. L., Dart R. C. Kidney failure and analgesic drugs. N Engl J Med. 1995 Jun 1;332(22):1515–1516. [PubMed] [Google Scholar]
  26. Johnson A. G. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging. 1998 Jan;12(1):17–27. doi: 10.2165/00002512-199812010-00003. [DOI] [PubMed] [Google Scholar]
  27. Johnson A. G., Nguyen T. V., Day R. O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994 Aug 15;121(4):289–300. doi: 10.7326/0003-4819-121-4-199408150-00011. [DOI] [PubMed] [Google Scholar]
  28. Johnson G. K., Tolman K. G. Chronic liver disease and acetaminophen. Ann Intern Med. 1977 Sep;87(3):302–304. doi: 10.7326/0003-4819-87-3-302. [DOI] [PubMed] [Google Scholar]
  29. Kaufman David W., Kelly Judith P., Rosenberg Lynn, Anderson Theresa E., Mitchell Allen A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002 Jan 16;287(3):337–344. doi: 10.1001/jama.287.3.337. [DOI] [PubMed] [Google Scholar]
  30. Konstam M. A., Weir M. R., Reicin A., Shapiro D., Sperling R. S., Barr E., Gertz B. J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001 Nov 6;104(19):2280–2288. doi: 10.1161/hc4401.100078. [DOI] [PubMed] [Google Scholar]
  31. Kuffner E. K., Dart R. C., Bogdan G. M., Hill R. E., Casper E., Darton L. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2001 Oct 8;161(18):2247–2252. doi: 10.1001/archinte.161.18.2247. [DOI] [PubMed] [Google Scholar]
  32. Kurth Tobias, Glynn Robert J., Walker Alexander M., Rexrode Kathryn M., Buring Julie E., Stampfer Meir J., Hennekens Charles H., Gaziano J. Michael. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003 Aug;42(2):234–244. doi: 10.1016/s0272-6386(03)00647-4. [DOI] [PubMed] [Google Scholar]
  33. Kwan D., Bartle W. R., Walker S. E. Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Dig Dis Sci. 1995 Sep;40(9):1951–1955. doi: 10.1007/BF02208663. [DOI] [PubMed] [Google Scholar]
  34. Lanas Angel, Serrano Pedro, Bajador Eduardo, Fuentes Javier, Sáinz Ricardo. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol. 2003 Feb;15(2):173–178. doi: 10.1097/00042737-200302000-00011. [DOI] [PubMed] [Google Scholar]
  35. Laporte J. R., Carné X., Vidal X., Moreno V., Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991 Jan 12;337(8733):85–89. doi: 10.1016/0140-6736(91)90744-a. [DOI] [PubMed] [Google Scholar]
  36. Levy M., Miller D. R., Kaufman D. W., Siskind V., Schwingl P., Rosenberg L., Strom B., Shapiro S. Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med. 1988 Feb;148(2):281–285. doi: 10.1001/archinte.148.2.281. [DOI] [PubMed] [Google Scholar]
  37. Lewis S. C., Langman M. J. S., Laporte Joan-Ramon, Matthews John N. S., Rawlins Michael D., Wiholm Bengt-Erik. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002 Sep;54(3):320–326. doi: 10.1046/j.1365-2125.2002.01636.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. MacDonald T. M., Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003 Feb 15;361(9357):573–574. doi: 10.1016/s0140-6736(03)12509-3. [DOI] [PubMed] [Google Scholar]
  39. Michel Beat A., Stucki Gerold, Frey Diana, De Vathaire Florent, Vignon Eric, Bruehlmann Pius, Uebelhart Daniel. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779–786. doi: 10.1002/art.20867. [DOI] [PubMed] [Google Scholar]
  40. Morgan Trefor, Anderson Adrianne. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens (Greenwich) 2003 Jan-Feb;5(1):53–57. doi: 10.1111/j.1524-6175.2003.00514.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Nelson E. B. Kidney failure and analgesic drugs. N Engl J Med. 1995 Jun 1;332(22):1514–1516. doi: 10.1056/NEJM199506013322213. [DOI] [PubMed] [Google Scholar]
  42. Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000 Mar 27;160(6):777–784. doi: 10.1001/archinte.160.6.777. [DOI] [PubMed] [Google Scholar]
  43. Perneger T. V., Whelton P. K., Klag M. J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994 Dec 22;331(25):1675–1679. doi: 10.1056/NEJM199412223312502. [DOI] [PubMed] [Google Scholar]
  44. Pope J. E., Anderson J. J., Felson D. T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993 Feb 22;153(4):477–484. [PubMed] [Google Scholar]
  45. Poulter N. Coronary heart disease is a multifactorial disease. Am J Hypertens. 1999 Oct;12(10 Pt 2):92S–95S. doi: 10.1016/s0895-7061(99)00163-6. [DOI] [PubMed] [Google Scholar]
  46. Rexrode K. M., Buring J. E., Glynn R. J., Stampfer M. J., Youngman L. D., Gaziano J. M. Analgesic use and renal function in men. JAMA. 2001 Jul 18;286(3):315–321. doi: 10.1001/jama.286.3.315. [DOI] [PubMed] [Google Scholar]
  47. Ruoff G. E. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther. 1998 May-Jun;20(3):376–375. doi: 10.1016/s0149-2918(98)80049-0. [DOI] [PubMed] [Google Scholar]
  48. Sica D. S., Schoolwerth A. C., Gehr T. WB. Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure. Congest Heart Fail. 2000 Sep-Oct;6(5):272–276. doi: 10.1111/j.1527-5299.2000.80169.x. [DOI] [PubMed] [Google Scholar]
  49. Sørensen H. T., Mellemkjaer L., Blot W. J., Nielsen G. L., Steffensen F. H., McLaughlin J. K., Olsen J. H. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000 Sep;95(9):2218–2224. doi: 10.1111/j.1572-0241.2000.02248.x. [DOI] [PubMed] [Google Scholar]
  50. Vasan R. S., Larson M. G., Leip E. P., Evans J. C., O'Donnell C. J., Kannel W. B., Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001 Nov 1;345(18):1291–1297. doi: 10.1056/NEJMoa003417. [DOI] [PubMed] [Google Scholar]
  51. Whelton A., Fort J. G., Puma J. A., Normandin D., Bello A. E., Verburg K. M., SUCCESS VI Study Group Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001 Mar-Apr;8(2):85–95. doi: 10.1097/00045391-200103000-00003. [DOI] [PubMed] [Google Scholar]
  52. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med. 2001 Feb 19;110 (Suppl 3A):33S–42S. doi: 10.1016/s0002-9343(00)00699-9. [DOI] [PubMed] [Google Scholar]
  53. Whelton Andrew, White William B., Bello Alfonso E., Puma Joseph A., Fort John G., SUCCESS-VII Investigators Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002 Nov 1;90(9):959–963. doi: 10.1016/s0002-9149(02)02661-9. [DOI] [PubMed] [Google Scholar]
  54. Wolz M., Cutler J., Roccella E. J., Rohde F., Thom T., Burt V. Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens. 2000 Jan;13(1 Pt 1):103–104. doi: 10.1016/s0895-7061(99)00241-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES